Osteoboost Vibration Belt for Low Bone Density Launches in U.S.

Osteoboost Health has launched Osteoboost, the first and only U.S. Food and Drug Administration (FDA)-cleared prescription medical device for low bone density.

According to the company, Osteoboost bridges the gap between next-gen consumer health tech and tested medical innovation. Designed for home use, the device delivers targeted vibration therapy to the spine and hips—areas at higher risk for osteoporotic fractures.

The technology was awarded breakthrough status from the FDA and approved through the de novo pathway. Its patented vibration tech was validated in a gold-standard randomized controlled trial to slow loss of vertebral bone density and strength.

The trial, conducted at the University of Nebraska Medical Center showed that Osteoboost slowed bone density and strength loss in postmenopausal women with osteopenia who used it at least three times weekly. There was 85% reduction in loss of spine bone density, 83% reduction of loss of spine bone strength, and 55% reduction of hip bone density.

“The longevity conversation is everywhere, but people rarely mention bone health even though it is fundamental to aging with confidence,” said Osteoboost Health CEO Laura Yecies. “Osteoboost empowers people to lead longer, stronger, and more active lives. And while the belt is sophisticated medical technology rigorously tested and validated for efficacy, the treatment is so easy – 30 minutes a day of gentle vibration therapy that can be done while walking, cooking, or other daily activities.”

Osteoboost recently secured its sixth U.S. patent. Last July, Osteoboost Health acquired Wellen, an online exercise and fall prevention platform designed for women with low bone density.